Trial Profile
An Randomized, Open Label, Multicenter Study to Compare the Efficacy and Safety of the Combination of Etanercept and Methotrexate With DMARD Therapy in Subjects With Active Early Rheumatoid Arthritis.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 18 May 2022
Price :
$35
*
At a glance
- Drugs Etanercept (Primary) ; Methotrexate (Primary) ; Disease-modifying antirheumatics
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms DOTAR
- Sponsors Pfizer; Wyeth
- 05 Jun 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 15 Nov 2008 New trial record.